Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: A model for potential treatment of nephrogenic systemic fibrosis

Journal of Cell Communication and Signaling

Volumn 6, Issue 2, 2012, Pages 97-105

  Riser, Bruce L ^a,b   Bhagavathula, Narasimharao ^c   Perone, Patricia ^c   Garchow, Kendra ^a   Xu, Yiru ^c   Fisher, Gary J ^c   Najmabadi, Feridoon ^a   Attili, Durga ^c   Varani, James ^c  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Gadolinium based contrast agent (GBCA); Matrix metalloproteinase 1 (MMP 1); Nephroblastoma overexpressed gene (NOV) CCN3 ; Nephrogenic systemic fibrosis (NSF); Platelet derived growth factor (PDGF); Tissue inhibitor of metalloprotienases 1 (TIMP 1)

Indexed keywords

GADODIAMIDE; INTERSTITIAL COLLAGENASE; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PLATELET DERIVED GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL PROLIFERATION; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; KIDNEY DYSFUNCTION; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION RESPONSE; RENAL PROTECTION; SKIN FIBROBLAST;

EID: 84863107768     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-012-0164-4     Document Type: Article

References (34)

1. Beyer C, Schett G, Distler O, Distler JHW (2010) Animal models of systemic scherosis: a review. Arthritis Rheum 62:2831-2844
2. Bhagavathula N, DaSilva M, Aslam MN, Dame MK, Warner RL, Xu Y, Fisher JG, Swartz R, Varani J (2009) Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol 44(8):433-439
3. Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J (2010) Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 45 (12):769-777
4. Borkham-Kamphorst E, van Roeyen CR, Van de Leur E, Floege J, Weiskirchen R (2012) CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC. J Cell Commun Signal 6 (1):11-25
5. Chevalier G, Yeger H, Martinerie C, Laurent M, Alami J, Schofield PN, Perbal B (1998) novH: differential expression in developing kidney and Wilm's tumors. Am J Pathol 152(6):1563-1575 (Pubitemid 28275014)
6. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000-1001
7. DaSilva M, O'Brien Deming M, Fligiel SE, Dame M, Johnson KJ, Swartz R, Varani J (2010) Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radio 45 (11):733-739
8. Del Galdo F, Wermuth PJ, Addya S, Addya S, Fortina P, Jimenez SA (2010) NFkappaB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 69(11):2024-2033
9. Deo A, Fogel M, Cowper SE (2007) Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2:264-267
10. Edward M, Quinn JA, Mukherjee S, Jensen M-BV, Jardine AG, Mark PB, Burden AD (2008) Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 214(5):584-593 (Pubitemid 351482273)
11. Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG (2010) Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 256(3):735-743
12. Fisher GJ, Wang ZQ, Datta SC, Talwar HS, Kang S, Varani J, Voorhees JJ (1996) Up-regulation of collagen- and elastin-degrading matrix metalloproteinases by doses of ultraviolet B light (UVB) too low to cause sunburn. Nature 379:335-339
13. Grobner T (2006) Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transpl 21:1104-1108
14. Khurana A, Runge VM, Narayanan M, Green JF, Nickel AE (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42:139-145 (Pubitemid 46104895)
15. MacNeil S, Bains S, Johnson C, Idee J-M, Factor C, Jestin G, Fretellier N, Morcos SK (2011) Gadolinium contrast agent associated stimulation of human fibroblast collagen production. Invest Radiol 46:711-717
16. Marckmann P, Skov L, Rossen K, DuPont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362 (Pubitemid 44300951)
17. McCallum L, Price S, Planque N, Perbal B, Pierce A, Whitton AD, Irvine AE (2006) A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108(5):1716-1723 (Pubitemid 44316142)
18. McNeill AM, Barr RJ (2002) Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Derm 41:364-367 (Pubitemid 34863309)
19. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jiminez SA (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheu 35:238-249 (Pubitemid 43185214)
20. Neudecker BA, Stern R, Mark LA, Steinberg S (2005) Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol 32:612-615 (Pubitemid 41415089)
21. Perone P, Weber S, DaSilva M, Varani J (2010) Collagenase activity is suppressed by elevated tissue inhibitor of metalloproteinase-1 (TIMP-1) in human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol 45:42-48
22. Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Del Galdo F, Jimenez SA (2010) Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis. doi:10.1136/ard127761
23. Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC (2009) CCN3 (Nov) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathology 174:1725-1734
24. Riser BL, Najmabadi F, Perbal B, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC, Peterson DR (2010) CCN3/CCN2 regulation and the fibrosis of diabetic renal disease. J Cell Commun Signal 1:39-50
25. Rydahl C, Thomsen H, Marckmann R (2008) High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to Gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43:141-144
26. Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J (2009) The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 61(6):537-552
27. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114:563-572 (Pubitemid 36577259)
28. van Roeyen CRC, Eitner F, Scholl T, Boor P, Kunter U, Planque N, Grone H-J, Bleau AM, Perbal B, Ostendorf T, Floege J (2008) CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 73:86-94 (Pubitemid 350273638)
29. Varani J, Perone P, Griffiths CEM, Kang S, Fisher GJ, Vorrhees (1994) All-trans retinoic acid (RA) stimulates events in organ-cultured human skin that underlie repair. Adult skin from sun-protected and sun-exposed sites responds in an identical manner to RA while neonatal foreskin responds differently. J Clin Invest 94:1747-1756
30. Varani J, DaSilva M, Warner RL, O'Brien Deming M, Barron AG, Johsnon KJ, Swartz R (2009) Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 44(2):74-81
31. Wermuth PJ, Del Galdo F, Jimenez SA (2009) Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 60(5):1508-1518
32. Wiesinger B, Kehlbach R, Bebin J, Hemsen J, Bartleon R, Schmehl J, Dietz K, Clausen CD, Wiskirchen J (2010) Effects of MRI contrast agents on human embryonic lung fibroblasts. Invest Radiol 45(9):513-519
33. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R (2007) Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2:258-263
34. Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR (2011) Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. J Am Coll Cardiol Img 4:1206-1216